>Dear Joan, Thank you so much for posting to the FAB list my request for
>documentation of the role of profit in directing pharmaceutical research.
>I only got a few replies, but they were extremely informative. I've
>collected them and pasted them in below.
>
>Through you, I'd like to give heartfelt thanks to everyone who took the
>time to respond. They really sent some terrific resources.
>
>All best,
>
>Alison.
>
>1.  Developing World Bioethics ISSN 1471-8731 (print); 1471-8847 (online)
>Volume 4 Number 1 2004
>THE DISTRIBUTION OF BIOMEDICAL RESEARCH RESOURCES AND INTERNATIONAL
>JUSTICE
>DAVID B. RESNIK
>
>2.  Wendy A. Rogers, "Evidence based medicine and justice: A framework for
>looking at the impact of EBM upon Vulnerable or disadvantaged groups,"
>JOURNAL OF MEDICAL ETHICS 2004; 30:141-145.
>
>
>3.  I have been working on access to anti-HIV drugs in Brazil,
>       patents and public health, last three years.
>
>       There lots of information on IP-health list that discusses
>       the role of intellectual property rights, pharmaceutical R&D,
>       private vs public interests in the field of health and
>       illness:
>       http://lists.essential.org/mailman/listinfo/ip-health
>
>       James Love (at CPTECH) has been rigthing a lot on the problem
>       http://www.cpetech.org/ip/health
>
>       There is also the DNDI Projet, an iniative on neglected
>       diseases http://www.dndi.org , and Medecin sans Frontire
>       Access to Drugs Campaing
>       http://www.accessmed-msf.org/dnd/dndi.asp , all related to
>       the question you ask for.
>
>4.  Marcia Angell, M.D., has written an essay on the issues inherent in
> >'offshore' research (to be published in a volume on bioethics, of which
> >I am co-editor, in December 2004). Marcia was executive editor of the
> >New England Journal of Medicine during the 1990s, when the scandals over
> >the AZT trials in Africa emerged (involving pregnant women who were
> >given placebos instead of the existing standard of care).  Her essay
> >speaks about the trials themselves and the ensuing ethical controversy,
> >but she also offers reflections on a) why companies were interested in
> >going offshore, as opposed to staying in the U.S., in the first place,
> >primarily to save money; b) what the incentives are for doing so (e.g.
> >FDA regulations make it far easier to go offshore than to conduct trials
> >here); c) her recommendations for ways to avoid this issue in the
> >future/ ensure ethical action on the part of researchers toward their
> >human subjects; d) an injunction that the only research that should be
> >done offshore is that which is specific and localized to a particular
> >population, that will benefit that population in particular, and that
> >cannot really be done elsewhere. She mentions malaria as a particular
>case.
>
>
>5.  Copyright  2004BusinessWorld Online, Inc. ALL RIGHTS RESERVED.
>MANILA, PHILIPPINES | Friday, July 16, 2004
>
>Commentary
>
>Drug firms: part of the AIDS problem or part of the solution?
>By WALDEN BELLO
>
>This speech was delivered at the debate on patents, drug development, and
>HIV/AIDS at the XV International AIDS Conference, Bangkok last July 14.
>Walden
>Bello is professor of sociology and public administration at the
>University of
>the Philippines and executive director of the Bangkok-based institute
>Focus on
>the Global South.